Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896317272> ?p ?o ?g. }
- W2896317272 endingPage "2179" @default.
- W2896317272 startingPage "2171" @default.
- W2896317272 abstract "Background Preterm delivery during pregnancy (<37 weeks' gestation) is a leading cause of perinatal mortality and morbidity. Treating bacterial vaginosis during pregnancy can reduce poor outcomes, such as preterm birth. We aimed to investigate whether treatment of bacterial vaginosis decreases late miscarriages or spontaneous very preterm birth. Methods PREMEVA was a double-blind randomised controlled trial done in 40 French centres. Women aged 18 years or older with bacterial vaginosis and low-risk pregnancy were eligible for inclusion and were randomly assigned (2:1) to three parallel groups: single-course or triple-course 300 mg clindamycin twice-daily for 4 days, or placebo. Women with high-risk pregnancy outcomes were eligible for inclusion in a high-risk subtrial and were randomly assigned (1:1) to either single-course or triple-course clindamycin. The primary outcome was a composite of late miscarriage (16–21 weeks) or spontaneous very preterm birth (22–32 weeks), which we assessed in all patients with delivery data (modified intention to treat). Adverse events were systematically reported. This study is registered with ClinicalTrials.gov, number NCT00642980. Findings Between April 1, 2006, and June 30, 2011, we screened 84 530 pregnant women before 14 weeks' gestation. 5630 had bacterial vaginosis, of whom 3105 were randomly assigned to groups in the low-risk trial (n=943 to receive single-course clindamycin, n=968 to receive triple-course clindamycin, and n=958 to receive placebo) or high-risk subtrial (n=122 to receive single-course clindamycin and n=114 to receive triple-course clindamycin). In 2869 low-risk pregnancies, the primary outcome occurred in 22 (1·2%) of 1904 participants receiving clindamycin and 10 (1·0%) of 956 participants receiving placebo (relative risk [RR] 1·10, 95% CI 0·53–2·32; p=0·82). In 236 high-risk pregnancies, the primary outcome occurred in 5 (4·4%) participants in the triple-course clindamycin group and 8 (6·0%) participants in the single-course clindamycin group (RR 0·67, 95% CI 0·23–2·00; p=0·47). In the low-risk trial, adverse events were more common in the clindamycin groups than in the placebo group (58 [3·0%] of 1904 vs 12 [1·3%] of 956; p=0·0035). The most commonly reported adverse event was diarrhoea (30 [1·6%] in the clindamycin groups vs 4 [0·4%] in the placebo group; p=0·0071); abdominal pain was also observed in the clindamycin groups (9 [0·6%] participants) versus none in the placebo group (p=0·034). No severe adverse event was reported in any group. Adverse fetal and neonatal outcomes did not differ significantly between groups in the high-risk subtrial. Interpretation Systematic screening and subsequent treatment for bacterial vaginosis in women with low-risk pregnancies shows no evidence of risk reduction of late miscarriage or spontaneous very preterm birth. Use of antibiotics to prevent preterm delivery in this patient population should be reconsidered. Funding French Ministry of Health." @default.
- W2896317272 created "2018-10-26" @default.
- W2896317272 creator A5000700013 @default.
- W2896317272 creator A5001471004 @default.
- W2896317272 creator A5003404957 @default.
- W2896317272 creator A5004303567 @default.
- W2896317272 creator A5011018095 @default.
- W2896317272 creator A5017322608 @default.
- W2896317272 creator A5020596238 @default.
- W2896317272 creator A5027979557 @default.
- W2896317272 creator A5028828562 @default.
- W2896317272 creator A5029505137 @default.
- W2896317272 creator A5032100596 @default.
- W2896317272 creator A5033564625 @default.
- W2896317272 creator A5034900223 @default.
- W2896317272 creator A5035137791 @default.
- W2896317272 creator A5036139228 @default.
- W2896317272 creator A5045592893 @default.
- W2896317272 creator A5047642156 @default.
- W2896317272 creator A5047751020 @default.
- W2896317272 creator A5049735718 @default.
- W2896317272 creator A5051655575 @default.
- W2896317272 creator A5052558365 @default.
- W2896317272 creator A5061464664 @default.
- W2896317272 creator A5066603873 @default.
- W2896317272 creator A5067156416 @default.
- W2896317272 creator A5081527636 @default.
- W2896317272 creator A5085048317 @default.
- W2896317272 date "2018-11-01" @default.
- W2896317272 modified "2023-10-12" @default.
- W2896317272 title "Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial" @default.
- W2896317272 cites W1511490662 @default.
- W2896317272 cites W1868667984 @default.
- W2896317272 cites W1971502646 @default.
- W2896317272 cites W1975755498 @default.
- W2896317272 cites W1991880863 @default.
- W2896317272 cites W1998861228 @default.
- W2896317272 cites W2015113632 @default.
- W2896317272 cites W2020044680 @default.
- W2896317272 cites W2022832304 @default.
- W2896317272 cites W2029943245 @default.
- W2896317272 cites W2043814908 @default.
- W2896317272 cites W2060858779 @default.
- W2896317272 cites W2061034329 @default.
- W2896317272 cites W2080017495 @default.
- W2896317272 cites W2081329471 @default.
- W2896317272 cites W2100576440 @default.
- W2896317272 cites W2112927272 @default.
- W2896317272 cites W2114695472 @default.
- W2896317272 cites W2117744093 @default.
- W2896317272 cites W2317894502 @default.
- W2896317272 cites W2322463613 @default.
- W2896317272 cites W2915941999 @default.
- W2896317272 cites W4249976463 @default.
- W2896317272 doi "https://doi.org/10.1016/s0140-6736(18)31617-9" @default.
- W2896317272 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30322724" @default.
- W2896317272 hasPublicationYear "2018" @default.
- W2896317272 type Work @default.
- W2896317272 sameAs 2896317272 @default.
- W2896317272 citedByCount "87" @default.
- W2896317272 countsByYear W28963172722018 @default.
- W2896317272 countsByYear W28963172722019 @default.
- W2896317272 countsByYear W28963172722020 @default.
- W2896317272 countsByYear W28963172722021 @default.
- W2896317272 countsByYear W28963172722022 @default.
- W2896317272 countsByYear W28963172722023 @default.
- W2896317272 crossrefType "journal-article" @default.
- W2896317272 hasAuthorship W2896317272A5000700013 @default.
- W2896317272 hasAuthorship W2896317272A5001471004 @default.
- W2896317272 hasAuthorship W2896317272A5003404957 @default.
- W2896317272 hasAuthorship W2896317272A5004303567 @default.
- W2896317272 hasAuthorship W2896317272A5011018095 @default.
- W2896317272 hasAuthorship W2896317272A5017322608 @default.
- W2896317272 hasAuthorship W2896317272A5020596238 @default.
- W2896317272 hasAuthorship W2896317272A5027979557 @default.
- W2896317272 hasAuthorship W2896317272A5028828562 @default.
- W2896317272 hasAuthorship W2896317272A5029505137 @default.
- W2896317272 hasAuthorship W2896317272A5032100596 @default.
- W2896317272 hasAuthorship W2896317272A5033564625 @default.
- W2896317272 hasAuthorship W2896317272A5034900223 @default.
- W2896317272 hasAuthorship W2896317272A5035137791 @default.
- W2896317272 hasAuthorship W2896317272A5036139228 @default.
- W2896317272 hasAuthorship W2896317272A5045592893 @default.
- W2896317272 hasAuthorship W2896317272A5047642156 @default.
- W2896317272 hasAuthorship W2896317272A5047751020 @default.
- W2896317272 hasAuthorship W2896317272A5049735718 @default.
- W2896317272 hasAuthorship W2896317272A5051655575 @default.
- W2896317272 hasAuthorship W2896317272A5052558365 @default.
- W2896317272 hasAuthorship W2896317272A5061464664 @default.
- W2896317272 hasAuthorship W2896317272A5066603873 @default.
- W2896317272 hasAuthorship W2896317272A5067156416 @default.
- W2896317272 hasAuthorship W2896317272A5081527636 @default.
- W2896317272 hasAuthorship W2896317272A5085048317 @default.
- W2896317272 hasBestOaLocation W28963172722 @default.
- W2896317272 hasConcept C126322002 @default.
- W2896317272 hasConcept C131872663 @default.
- W2896317272 hasConcept C142724271 @default.
- W2896317272 hasConcept C168563851 @default.